Business
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
WALTHAM, Mass., June 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., June 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 8:40 a.m. ET.\n\nA live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.\nAbout Syndax\nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the CSF-1 receptor. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.\nSyndax ContactSharon KlahreSyndax Pharmaceuticals, [email protected] 781.684.9827\nSNDX-G\n\n View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-goldman-sachs-45th-annual-global-healthcare-conference-302163121.html\nSOURCE Syndax Pharmaceuticals, Inc.","length":3397,"tagName":"div"}]